Pellepharm, Inc

10 S La Salle St Ste 3300
Chicago, IL 60603

PellePharm, Inc., based in Chicago, IL, is a biotechnology company dedicated to targeting rare dermatological diseases, particularly Gorlin Syndrome and Basal Cell Carcinomas (BCCs), at their source. With a strong commitment to precision medicine, PellePharm aims to develop innovative treatments that enhance the quality of life for patients living with these conditions.

The company is engaged in partnerships with organizations such as the Gorlin Syndrome Alliance and LEO Pharma to advance its research and development efforts. Currently, PellePharm is focused on patidegib, an investigational topical treatment designed to reduce tumor burden in patients affected by Gorlin Syndrome and BCCs, as there are no FDA-approved drugs available for this condition.

Generated from the website

Also at this address

Own this business?
See a problem?

You might also like

Orphazyme

Orphazyme is a biopharmaceutical company based in Chicago, IL that focuses on developing treatments for rare genetic diseases. With a commitment to innovative research and patient-centered care, Orphazyme strives to address unmet medical needs and improve the lives of individuals affected by these conditions. Generated from their business information
Drugs and drug proprietaries

Xeris Pharmaceuticals, Inc

Xeris Pharmaceuticals, Inc., based in Chicago, is dedicated to enhancing patient well-being through the creation and distribution of advanced, pre-prepared therapeutic medications. With a focus on innovation, Xeris Pharmaceuticals strives to provide convenient and effective treatment options that positively impact the lives of those in need. Generated from their website's infomation
Drugs and drug proprietaries

Altathera Pharmaceuticals

AltaThera Pharmaceuticals, based in Chicago, IL, is a precision medicine company dedicated to enhancing patient care through innovative science and individualized treatment solutions for cardiovascular drug therapy. With a focus on addressing the global arrhythmia epidemic, AltaThera is committed to bridging the gap between scientific innovation and clinical decision-making. The company's flagship product, Sotalol IV, represents a new formulation of a trusted antiarrhythmic drug that aims to streamline patient care by converting inpatient procedures to outpatient settings, ultimately reducing hospital stays. By leveraging clinical data to optimize the use of existing medications, AltaThera strives to improve treatment outcomes for diverse patient populations. Generated from the website
United States›Illinois›Chicago›Pellepharm, Inc

Partial Data by Infogroup (c) 2025. All rights reserved.